Erectile Dysfunction (ED) Drugs Market to grow by USD 1.44 billion from 2023-2028, North America to account for 41% of market growth - Technavio
NEW YORK, Dec. 14, 2023 /PRNewswire/ --
How much is the expected growth in the Erectile Dysfunction (ED) Drugs Market size from 2023 to 2028 and How is the market categorized based on end-users, products, and geography?
The erectile dysfunction (ED) drugs market size is expected to grow by USD 1.44 billion from 2023 to 2028. In addition, the momentum of the market will progress at a CAGR of 6.67% during the forecast period, according to Technavio Research. The market is categorized based on End-user (Hospital pharmacy, Retail pharmacy, and Online pharmacy), Product (Oral drugs, Topical drugs, and Others), and Geography (North America, Europe, Asia, and Rest of World (ROW)). North America will contribute 41% to the growth of the global market during the forecast period. The increasing prevalence of chronic diseases is one of the major factors driving market growth. Furthermore, menopausal symptoms, including vulvovaginal and clitoral atrophic change, vaginal thinning, and decreased elasticity, further result in dryness and the onset of dyspareunia. In developed countries such as the US, the economic status of the population is favorable, helping them opt for expensive alternative modes of treatment. This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read a PDF Sample Report
Company Profile:
Bayer AG, Cadila Pharmaceuticals Ltd., Cipla Ltd., Dong A Socio Holdings Co. Ltd., Dr Reddys Laboratories Ltd., Eli Lilly and Co., Endo International Plc, Futura Medical plc, Innovcare Lifesciences Pvt. Ltd., Lupin Ltd., Pfizer Inc., SK Inc., Teva Pharmaceutical Industries Ltd., TTK Healthcare Ltd., Viatris Inc., VIVUS LLC
Who is the manufacturer of Edex, an erectile dysfunction drug?
Endo International Plc: The company offers erectile dysfunction drugs namely Edex.
To gain access to more vendor profiles available with Technavio, buy the report!
What is the significance of the hospital pharmacy segment during the forecast period?
The hospital pharmacy segment will be significant during the forecast period. This segment comprises pharmaceuticals that are purchased directly by hospitals from different pharmaceutical companies. These pharmaceuticals are used for the treatment of either outpatients or inpatients. Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a PDF Sample Report
"Besides analyzing the current market scenario, our report examines historic data from 2017 to 2021"- Technavio
Where is awareness of ED experiencing a significant increase?
Driver
Rising demand for ED drugs
Rising awareness of ED
High prevalence of conditions resulting in ED
The rising demand for ED drugs drives market growth. The OTC availability of drugs paired with the increase in the number of prescriptions for ED drives the demand. Furthermore, due to the availability of treatment guidelines, physicians are using drug therapies for the treatment of ED.
The presence of novel drug formulations in the late stages of development is an emerging market trend.
Strategic alliances among market vendors are a key trend in the erectile dysfunction (ED) drugs market. Identify key trends, drivers, and challenges in the market. Download a sample report to gain access to this information.
Related Reports:
The US - Premature Ejaculation (PE) Disorder Therapeutics Market size is estimated to grow by USD 478.41 million at a CAGR of 10.22% between 2023 and 2028.
The Premature Ejaculation (PE) Treatment Market size is estimated to grow by USD 1,459.85 million at a CAGR of 8.78% between 2023 and 2028.
What are the key data covered in this erectile dysfunction (ED) drugs market report?
CAGR of the market during the forecast period
Detailed information on factors that will drive the growth of the erectile dysfunction (ED) drugs market between 2023 and 2028.
Precise estimation of the erectile dysfunction (ED) drugs market size and its contribution to the market in focus on the parent market
Accurate predictions about upcoming trends and changes in consumer behavior
Growth of the erectile dysfunction (ED) drugs market across North America, Europe, Asia, and ROW
A thorough analysis of the market's competitive landscape and detailed information about vendors
Comprehensive analysis of factors that will challenge the growth of erectile dysfunction (ED) drugs market vendors.
ToC:
Executive Summary
Market Landscape
Market Sizing
Historic Market Sizes
Five Forces Analysis
Market Segmentation by End-user
Market Segmentation by Product
Market Segmentation by Geography
Customer Landscape
Geographic Landscape
Drivers, Challenges, & Trends
Company Landscape
Company Analysis
Appendix
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/erectile-dysfunction-ed-drugs-market-to-grow-by-usd-1-44-billion-from-2023-2028--north-america-to-account-for-41-of-market-growth---technavio-302015284.html
SOURCE Technavio
